Prenatal testing and newborn screening tests are diagnostic tests to detect any possible birth defects that may be there in the baby. These are useful in determining the health of the baby. The main diagnostic types of prenatal testing and newborn screening are non-invasive and invasive. Invasive diagnostic testing necessitates puncturing the skin or invading the body. A few examples include blood testing, biopsies, and colonoscopies. The different technologies include screening technology, diagnostic technology and is used in various sectors such as hospitals, and diagnostic centres. The prenatal testing and newborn screening tests market research report is one of a series of new reports from The Business Research Company that provides prenatal testing and newborn screening tests market statistics, including prenatal testing and newborn screening tests industry global market size, regional shares, competitors with prenatal testing and newborn screening tests market share, detailed prenatal testing and newborn screening tests market segments, market trends and opportunities, and any further data you may need to thrive in the prenatal testing and newborn screening tests industry. This prenatal testing and newborn screening tests market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global prenatal testing & newborn screening market grew from $5.04 billion in 2022 to $5.65 billion in 2023 at a compound annual growth rate (CAGR) of 12.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The prenatal testing & newborn screening market is expected to grow from $8.87 billion in 2027 at a CAGR of 11.9%. The high prevalence of genetic diseases in infants contributed to the growth of the prenatal testing and newborn screening market. According to the World Health Organization, genetic disease includes diseases such as Thalassemia, Sickle Cell Anaemia, Haemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome, Huntington’s disease. The sickle cell anaemia is one of the genetic diseases that affects millions throughout the world, and the disease is particularly common among people whose ancestors are from Africa, America, Cuba, Central America, Saudi Arabia, and India. According to data published in 2020 by the Centres for Disease Control and Prevention, a national public health agency of the United States, 5,568 babies were affected by Trisomy 21 (Down syndrome), 1,187 babies were affected by Trisomy 18 (Edwards syndrome), and 531 babies were affected by Trisomy 13 (Patau syndrome). The high prevalence of genetic diseases in infants boosted the demand for prenatal testing and newborn screening market. Growth of the prenatal testing and newborn screening market may be hampered by the relatively low healthcare access in most developing countries, compared to the developed nations. For instance, in India, there were only about 1.9 million hospital beds for 1.33 billion people, as of 2020. Low access to healthcare services and the lack of sufficient hospitals and healthcare professionals harmed market growth in many developing nations. Moreover, low disposable income in many countries further lowers the access to healthcare services, thus negatively hampering the growth of the prenatal testing and newborn screening market. The use of machine learning and artificial intelligence is gradually gaining popularity in the prenatal testing and newborn screening market. Artificial intelligence (AI) is the simulation of human intelligence in machines. Machine learning is a part of AI. Machine learning and AI help companies in the prenatal testing and newborn screening market to conduct a detailed analysis of all relevant data, provide insights about different diseases, and offer a more accurate evaluation of tissue samples. For instance, In September 2021, Sema4, a US-based AI-driven genomic and clinical data intelligence platform company, launched Sema4 Elements. Sema4 Elements are genetic solutions that are information-driven, digital tools for patients and providers, and services that let doctors manage patients holistically throughout their journeys with reproductive and generational health, using artificial intelligence. In March 2020, Thermo Fisher Scientific Inc. announced its decision to acquire Qiagen for $11.5 billion. Thermo Fisher has a specialty diagnostics capability, that includes allergy, autoimmunity, transplant diagnostics, and oncology testing. The acquisition is expected to complement Thermo Fisher’s genetic analysis and bioscience capabilities. Qiagen is a Germany-based genetic tester that was founded in 1984 and operates more than 35 offices in over 25 countries. Major players in the prenatal testing and newborn screening market are PerkinElmer, Progenity, Laboratory Corporation of America Holdings (Sequenom), Natera, Invitae, Centogene, Cradle Genomics, Roche Diagnostics, Quest Diagnostics and Baebies. North America was the largest region in the prenatal testing and newborn screening market in 2022. Western Europe was the second largest region in the global prenatal testing and newborn screening market. The regions covered in the global prenatal testing and newborn screening tests market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the prenatal testing and newborn screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The prenatal testing and newborn screening tests market includes revenues earned by entities by providing blood test services, hearing test services, CCHD screening tests, and non-invasive tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global prenatal testing & newborn screening market is segmented - 1) By Diagnostic Type: Non-Invasive, Invasive 2) By Technology: Screening Technology, Diagnostic Technology 3) By End user: Hospitals, Diagnostic centers

Fertility treatment is a medical treatment provided to a man or a woman to increase their chances of bearing an offspring. It is used to treat infertile patients. Hormone and ovulation-supporting medicines are frequently used in fertility treatments, sometimes in conjunction with minor surgical procedures. The main product types of fertility are reagents, and equipment. A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The treatments are performed on female and male in fertility clinics, hospitals, surgical centers, and clinical research institutes. The fertility treatment market research report is one of a series of new reports from The Business Research Company that provides fertility treatment market statistics, including fertility treatment industry global market size, regional shares, competitors with a fertility treatment market share, detailed fertility treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fertility treatment industry. This fertility treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fertility treatments market grew from $15.26 billion in 2022 to $16.48 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The fertility treatments market is expected to grow from $22.77 billion in 2027 at a CAGR of 8.4%. The growth in the median age of first-time motherhood combined with change in lifestyle increased the difficulty of conceiving, increasing the demand for fertility treatment. The median age of first-time motherhood has increased all over the globe due to late marriages, contraceptive techniques, and an increase in the number of women who prioritize their careers over starting a family. In 2020, the average age of first-time mothers in America has risen from 21 to 26. Women in other developed countries are also deferring, with the typical first birth occurring at the age of 31 for new mothers. In this scenario, a growing number of women are opting for IVF treatments, which is expected to drive this market. The high cost and low success rate of In vitro fertilization (IVF) treatment is a major factor that limits the growth of the fertility treatments market. In vitro fertilization is a fertilization process in which an egg is fertilized with sperm outside the body, in vitro. In vitro fertilization (IVF) treatment costs differ in many countries due to the lack of refund policies. Moreover, insurance companies usually do not cover infertility treatments. According to the American society of reproductive medicine, in the USA, the average cost of an IVF cycle is $12,400 and the average cost of an IVF cycle using fresh embryos is $8,158 with a median cost at $7,500. The rate of success of IVF treatments is only 28% to 35%, which decreases with the increase in woman's age. For example, for women, the success rate is 32.2% under 35 and 1.9% for women aged over 44. Thus, the high cost and low success rate of IVF treatment restrict the growth of the fertility treatment market. Development of new techniques to treat infertility using a human’s body is a key trend in the fertility treatments market. INVOcell is an IVF alternative that uses the woman’s body to support fertilization, thus eliminating the cost of a laboratory incubator. The INVOcell device is placed with the eggs and sperm in the vaginal cavity, allowing for the stability of the natural environment, pH, and gas to help in fertilization. INVOcell, which is made in Medford, Massachusetts by INVO Bioscience, costs around $6,800 including medication. Although IVF generated more quality embryos, the birth rates between IVF and INVOcell are similar. According to the journal of assisted reproduction and genetics, 12 out of 20 women gave birth to 15 babies in IVF including three sets of twins and 11 out of 20 women gave birth to 16 babies in INVOcell group including five sets of twins. In August 2022, CCRM Fertlity, an American fertility treatment company, acquired Institute for Reproductive Medicine & Sciences (IRMS) for an undisclosed amount. The acquisition would add world class proprietary reproductive medicine offerings to the CCRM’s portfolio and expand its footprint across 11 major metropolitan areas with 34 locations across the US and Canada. Institute for Reproductive Medicine and Science (IRMS) is a US-based fertility research and treatment company having its presence in major metropolitan areas. Major players in the fertility treatment market are Apollo Hospitals Enterprise Ltd., Care Fertility Group, Genea Limited, The Johns Hopkins Health System Corp., Medicover Group, Monash IVF Group, Progyny Inc., Vitrolife, Carolinas Fertility Institute, OvaScience Inc., Xytex Cryo International, Merck KGaA, Cook Medical, CooperSurgical Inc., Instituto Bernabeu, INVO Bioscience, The Cooper Companies Inc., Virtus Health, CryoChoice LLC., Millendo Therapeutics Inc., FUJIFILM Irvine Scientific, LABOTECT GMBH, Fertility Focus, Olympus Corporation, Irvine Scientific sales Company Inc., and Ferring Pharmaceuticals. North America was the largest region in the fertility treatment market in 2022. Western Europe was the second largest region in the global fertility treatment market. The regions covered in the global fertility treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fertility treatment market includes revenues earned by entities by providing medicinal services, surgical services, and assisted services such as in vitro fertilization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fertility treatments market is segmented - 1) By Product: Reagents, Equipment 2) By End-User: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By Patient Type: Female, Male

Fertility treatment is a medical procedure intended to increase the chances of conceiving a child. These services are used to increase the chances of bearing a child. The main types of services in fertility services are fresh non-donor, frozen non-donor, egg and embryo banking, fresh donor, and frozen donor. Donor eggs are collected and immediately ertilized with the male partner’s sperm in a fresh donor egg IVF cycle, with the developing fresh embryos being delivered to the recipient. The leftover embryos can be preserved and used in future frozen embryo transfers. The different procedures include assisted reproductive technology (ART), in-vitro fertilization, artificial insemination and is used by both male, female. The fertility services market research report is one of a series of new reports from The Business Research Company that provides fertility services market statistics, including fertility services industry global market size, regional shares, competitors with a fertility services market share, detailed fertility services market segments, market trends and opportunities, and any further data you may need to thrive in the fertility services industry. This fertility services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fertility services market size will grow from $47.17 billion in 2022 to $54.12 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global fertility services market size is expected to grow to $90.14 billion in 2027 at a CAGR of 13.6%. Growing infertility rates are anticipated to boost the demand for fertility services during the forecast period. Various social and environment-related factors such as lifestyle changes including obesity, stress or depression, and high consumption of alcohol contribute to a surge in infertility rates, thereby generating the high requirement for fertility services. For example, in 2020, according to NPR, a US-based non-profit media organization, there were 4% fewer babies born in the United States in 2020 than in 2019. The preliminary figures showed that the overall fertility rate hit yet another record low, at 55.8 births per 1,000 women aged 15 to 44. Thus, growing infertility rates will drive the demand for fertility services. The high cost of fertility services is expected to limit the growth of the fertility services market. The cost of in-vitro fertilization (IVF) primarily depends on infertility workup and varies from person to person. For instance, the average cost of one in-vitro fertilization (IVF) cycle is $12,000. The range of cost involved in one IVF cycle can be between $10,000 and $15,000, which excludes the cost of medication which may be as low as $1,500 or as high as $3,000 per cycle. The IVF cost is continuously rising attributing to modern diagnostic tests and various treatment methods such as hysteroscopy, IUI, and laparoscopy being used to facilitate and aid infertility treatment cost. Therefore, the high cost of fertility treatment is to act as a major challenge for the development of the fertility services market. Companies in the fertility services market have witnessed significant growth in the number of research collaborations as well as research funding approvals. Key companies operating in the market are projected to increase their R&D expenditure to introduce new advanced techniques and drugs used for fertility treatments. For instance, in October 2022, Maven Clinic, a US-based company specializing in telemedicine-based virtual clinic for women's and family health, collaborated with Indira IVF. The collaboration aimed at providing access to Maven members in India to Indira IVF's high-quality clinical care, other perks, and the best virtual family-building care available through the Maven platform. Indira IVF is an India-based infertility speciality clinic chain. Furthermore, in February 2021, CooperSurgical, a US-based company specializing in women’s health care solutions, collaborated with Virtus Health. The collaboration aimed at emphasizing on digitalization, cryogenics, and reproductive genetics, the cooperation will lead initiatives to assist patients' fertility journeys, including those who require egg, sperm, or embryo donations. Virtus Health is an Australia-based company specializing in fertility services. In December 2021, CooperCompanies, a US-based company specializing in women’s healthcare solutions, acquired Generate Life Sciences for $1.6 billion. Through this acquisition, CooperSurgical offers an even stronger selection of fertility centres and OB/GYNs. Generate Life Sciences is a US-based provider of donor eggs and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage. Major players in the fertility services market are Merck KGaA, Care Fertility, INVO Bioscience, Vitrolife, Monash IVF Group, Carolinas Fertility Institute, IntegraMed, Inc., New Hope Fertility Centre and Apollo Hospitals Enterprise Ltd. Western Europe was the largest region in the fertility services market in 2022. North America was the second largest region in global fertility services market. The regions covered in the global fertility services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The fertility services market includes revenues earned by entities by providing artificial insemination, and intrauterine insemination. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global fertility services market is segmented - 1) By Procedure: Assisted Reproductive Technology (ART), In-Vitro Fertilization, Artificial Insemination 2) By Service: Fresh Non-Donor, Frozen Non-Donor, Egg and Embryo Banking, Fresh Donor, Frozen Donor 3) By Application: Male, Female

Technology advisory refers to services that offer advice on developing technology strategies, technology ideation and prototyping, designing digital consulting services, and cybersecurity enhancements. Technology advisory help to create an effective IT strategy, adjust operations to meet corporate objectives, invest in the appropriate technology and implement it, adopt the shifting IT landscape, keep up with the latest technology developments, enhance enterprise architecture, manage and improve IT expenses. The main types of technology advisory services are application development, cloud services, cybersecurity and privacy, data and analytics, technology strategy and enterprise architecture, and others. Application development refers to the process of building a computer program or a series of programs to fulfil the many functions that a business requires. The different industries include banking, financial services, healthcare, IT and telecom, government, and others and involve various sizes of enterprises such as large enterprises and small and medium-sized enterprises. The technology advisory market research report is one of a series of new reports from The Business Research Company that provides technology advisory market statistics, including technology advisory industry global market size, regional shares, competitors with a technology advisory market share, detailed technology advisory market segments, market trends and opportunities, and any further data you may need to thrive in the technology advisory industry. This technology advisory market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global technology advisory market size will grow from $154.47 billion in 2022 to $161.32 billion in 2023 at a compound annual growth rate (CAGR) of 4.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global technology advisory market size is expected to grow to $184.7 billion in 2027 at a CAGR of 3.4%. The increasing requirement for simplifying business operating models and IT investment monitoring is a major driver contributing to the growth of the technology advisory market. Technology consulting firms help companies integrate technology into their business operations and create better experiences, thereby improving business processes, reducing costs, and maximizing technology-based opportunities. Technology advisory firms also help companies address cybersecurity concerns and keep data safe. For instance, Louis Vuitton uses technology consulting to create small modules in business and IT strategy and IT governance to run its operations effectively. In addition to this, companies such as Canon and Samsung have been using technology advice to optimize their operations and reduce IT costs. Technology advisory services help companies focus more on core business, access the latest technology, and minimize hardware failure, virus and spyware attacks, and database corruption. Security and reliability concerns are expected to limit the growth of the technology advisory market. Security hacks, illegal surveillance, lack of transparency, misuse of personal data, and algorithmic bias are some of the key factors that have come along with increased technological advancement. According to Verizon’s 2021 Data Breach Investigations Report, the info-tech sector is highly susceptible to external (66%) and internal (37%) threats, industrial espionage (9%), and financial motives (88%). For example, according to security tracker Firefox Monitor, Paytm Mall, a premier shopping app, experienced a major data breach that affected nearly 3.4 million customers in 2020. Organizations today rely very much on applications and IT software to conduct business. Software defects resulting in unauthorized access and the use of malicious intruders and malicious code to breach the security of the system are adding more to the security and reliability of third-party technology advisory services and hence restraining the market growth. Artificial Intelligence (AI) is a leading trend gaining traction in various business processes. AI is an amalgamation of different technologies that enables a machine to sense, understand, and act. AI helps businesses identify and solve business problems and drive measurable business value. AI helps in designing hardware infrastructure - on-premise or cloud-based, ingestion, and analysis of big data, and to enable flexibility of computing resources. For instance, in 2022, Tech Mahindra launched YANTR.AI, a cognitive artificial intelligence (AI) solution that automates and simplifies field services. With YANTR.AI, operational efficiency, productivity, and workflow control are enhanced by combining advanced analytics, artificial intelligence (AI), machine learning (ML), and optimisation with people, allowing field operations to be hyper-automated, thus increasing efficiency and customer satisfaction. With the improvement in AI technology with every passing day, it is gaining huge importance in data expertise, business processes, and workflow management. In October 2020, Accenture PLC., an Ireland-based global professional services company providing services in strategy, consulting, technology, and operations, acquired SALT Solutions AG, a German technology consultancy, for an undisclosed amount. The acquisition is expected to help Accenture plc build a cloud-based industrial internet-of-things (IoT) platform that will enable the client to reduce quality and waste issues in the whole supply chain. SALT has deep expertise in manufacturing and supply chain systems, complementing Accenture's expertise in cloud solutions and planning systems. The acquisition will help Accenture to expand its digital manufacturing and operations business in Germany. SALT Solutions AG is a German technology consultancy company implementing and maintaining IT systems for a variety of companies across different sectors. Major players in the technology advisory market are Fujitsu Ltd., HCL Technologies Limited, Booz & Co., Infosys Limited, Dell Technologies Inc., KPMG, IBM Corporation, Tata Consultancy Services Limited, Ernst & Young (EY) and McKinsey & Company. North America was the largest region in the technology advisory market in 2022. Western Europe was the second largest region in the global technology advisory market. The regions covered in the global technology advisory market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the technology advisory market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The technology advisory market consists of revenue earned by entities that provide advisory services to clients to identify, prioritize, design, and manage their investments in a various advanced technology. Technology advisory services provide consultancy on developing technology strategies, technology ideation and prototyping, design digital consulting services, and ways to enhance cybersecurity. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global technology advisory market is segmented - 1) By Service: Application development, Cloud Services, Cybersecurity and Privacy, Data and Analytics, Technology Strategy and Enterprise Architechture, Other Services 2) By End Use: Banking, Financial Services, Healthcare, IT & telecom, Government, Other End Uses 3) By Enterprise Size: Large Enterprise, Small and Medium Enterprise

Technology advisory refers to services that offer advice on developing technology strategies, technology ideation and prototyping, designing digital consulting services, and cybersecurity enhancements. Technology advisory help to create an effective IT strategy, adjust operations to meet corporate objectives, invest in the appropriate technology and implement it, adopt the shifting IT landscape, keep up with the latest technology developments, enhance enterprise architecture, manage and improve IT expenses. The main types of technology advisory services are application development, cloud services, cybersecurity and privacy, data and analytics, technology strategy and enterprise architecture, and others. Application development refers to the process of building a computer program or a series of programs to fulfil the many functions that a business requires. The different industries include banking, financial services, healthcare, IT and telecom, government, and others and involve various sizes of enterprises such as large enterprises and small and medium-sized enterprises. The technology advisory market research report is one of a series of new reports from The Business Research Company that provides technology advisory market statistics, including technology advisory industry global market size, regional shares, competitors with a technology advisory market share, detailed technology advisory market segments, market trends and opportunities, and any further data you may need to thrive in the technology advisory industry. This technology advisory market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global technology advisory market size will grow from $154.47 billion in 2022 to $161.32 billion in 2023 at a compound annual growth rate (CAGR) of 4.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global technology advisory market size is expected to grow to $184.7 billion in 2027 at a CAGR of 3.4%. The increasing requirement for simplifying business operating models and IT investment monitoring is a major driver contributing to the growth of the technology advisory market. Technology consulting firms help companies integrate technology into their business operations and create better experiences, thereby improving business processes, reducing costs, and maximizing technology-based opportunities. Technology advisory firms also help companies address cybersecurity concerns and keep data safe. For instance, Louis Vuitton uses technology consulting to create small modules in business and IT strategy and IT governance to run its operations effectively. In addition to this, companies such as Canon and Samsung have been using technology advice to optimize their operations and reduce IT costs. Technology advisory services help companies focus more on core business, access the latest technology, and minimize hardware failure, virus and spyware attacks, and database corruption. Security and reliability concerns are expected to limit the growth of the technology advisory market. Security hacks, illegal surveillance, lack of transparency, misuse of personal data, and algorithmic bias are some of the key factors that have come along with increased technological advancement. According to Verizon’s 2021 Data Breach Investigations Report, the info-tech sector is highly susceptible to external (66%) and internal (37%) threats, industrial espionage (9%), and financial motives (88%). For example, according to security tracker Firefox Monitor, Paytm Mall, a premier shopping app, experienced a major data breach that affected nearly 3.4 million customers in 2020. Organizations today rely very much on applications and IT software to conduct business. Software defects resulting in unauthorized access and the use of malicious intruders and malicious code to breach the security of the system are adding more to the security and reliability of third-party technology advisory services and hence restraining the market growth. Artificial Intelligence (AI) is a leading trend gaining traction in various business processes. AI is an amalgamation of different technologies that enables a machine to sense, understand, and act. AI helps businesses identify and solve business problems and drive measurable business value. AI helps in designing hardware infrastructure - on-premise or cloud-based, ingestion, and analysis of big data, and to enable flexibility of computing resources. For instance, in 2022, Tech Mahindra launched YANTR.AI, a cognitive artificial intelligence (AI) solution that automates and simplifies field services. With YANTR.AI, operational efficiency, productivity, and workflow control are enhanced by combining advanced analytics, artificial intelligence (AI), machine learning (ML), and optimisation with people, allowing field operations to be hyper-automated, thus increasing efficiency and customer satisfaction. With the improvement in AI technology with every passing day, it is gaining huge importance in data expertise, business processes, and workflow management. In October 2020, Accenture PLC., an Ireland-based global professional services company providing services in strategy, consulting, technology, and operations, acquired SALT Solutions AG, a German technology consultancy, for an undisclosed amount. The acquisition is expected to help Accenture plc build a cloud-based industrial internet-of-things (IoT) platform that will enable the client to reduce quality and waste issues in the whole supply chain. SALT has deep expertise in manufacturing and supply chain systems, complementing Accenture's expertise in cloud solutions and planning systems. The acquisition will help Accenture to expand its digital manufacturing and operations business in Germany. SALT Solutions AG is a German technology consultancy company implementing and maintaining IT systems for a variety of companies across different sectors. Major players in the technology advisory market are Fujitsu Ltd., HCL Technologies Limited, Booz & Co., Infosys Limited, Dell Technologies Inc., KPMG, IBM Corporation, Tata Consultancy Services Limited, Ernst & Young (EY) and McKinsey & Company. North America was the largest region in the technology advisory market in 2022. Western Europe was the second largest region in the global technology advisory market. The regions covered in the global technology advisory market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the technology advisory market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The technology advisory market consists of revenue earned by entities that provide advisory services to clients to identify, prioritize, design, and manage their investments in a various advanced technology. Technology advisory services provide consultancy on developing technology strategies, technology ideation and prototyping, design digital consulting services, and ways to enhance cybersecurity. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products. The global technology advisory market is segmented - 1) By Service: Application development, Cloud Services, Cybersecurity and Privacy, Data and Analytics, Technology Strategy and Enterprise Architechture, Other Services 2) By End Use: Banking, Financial Services, Healthcare, IT & telecom, Government, Other End Uses 3) By Enterprise Size: Large Enterprise, Small and Medium Enterprise

IVF is a process of fertilization where an egg is combined with sperm outside the body, in vitro ("in glass”). In vitro fertilization (IVF) is a sophisticated set of treatments intended to improve fertility, avoid genetic issues, and aid in child conception. It is used to address infertility. The main types of cycles in IVF services markets are fresh IVF cycles (non-donor), thawed IVF cycles (non-donor), and donor egg IVF cycles. When an IVF cycle is completed utilizing eggs and embryos that have never been frozen, it is referred to as a fresh IVF cycle. After the eggs are extracted, they are fertilized in the lab with semen. The different service providers include fertility clinics, hospitals, surgical centres, clinical research institutes and is used in various sectors such as fertility clinics, hospitals, and other settings. The IVF services market research report is one of a series of new reports from The Business Research Company that provides IVF services market statistics, including IVF services industry global market size, regional shares, competitors with a IVF services market share, detailed IVF services market segments, market trends and opportunities, and any further data you may need to thrive in the IVF services industry. This IVF services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ivf services market size will grow from $15.38 billion in 2022 to $17.13 billion in 2023 at a compound annual growth rate (CAGR) of 11.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global ivf services market size is expected to grow to $25.27 billion in 2027 at a CAGR of 10.2%. The rising infertility rate contributed to the growth of the in vitro fertilization (IVF) services market. Infertility is known as the inability to conceive within 12 months. According to the US Department of Health and Human Services, around 12 to 13 couples in 100 have a problem in conceiving. Moreover, according to the Indian Journal of Community Medicine, 15 to 20 million infertility cases are in India alone. The rising infertility rate made people resort to IVF services contributing to the growth of the market. The high cost of IVF services limits the in-vitro fertilization (IVF) services market. For instance, the cost of a basic IVF package ranges from $4,700 to $20,000, and the average price in the USA is around $12,000. The total cost of a single IVF cycle can range between $8,000 to $30,000. According to FertilityIQ, the cost of IVF services was around $22,000. In emerging economies like India, the cost of IVF services ranges from INR 70,000 to INR 300,000. The high cost of IVF services makes it unavailable to low- and middle-income populations negatively affecting the IVF services' market growth. Platelet-rich plasma (PRP) is the latest technique increasingly used for improving IVF success rate in patients with recurrent implantation failures. PRP is used alongside fertility treatments like IVF to improve egg quality, uterine lining thickness and endometrial receptivity, and the treatment is primarily for recurrent implantation failure over multiple IVF cycles. According to an article published by the Journal of Assisted Reproduction and Genetics, women treated with PRP experienced a significant improvement in Follicle-Stimulating Hormone (FSH), Anti-Müllerian Hormone (AMH), and Antral Follicle Count (AFC) and help improve fertility. In December 2020, Fresenius Helios, a Germany-based healthcare company acquired Eugin Group for $ 195.98 million (€160 million). The acquisition expands Fresenius Helios's global network of fertility clinics, providing tremendous growth and consolidation potential. Eugin Group is a Spain-based company that provides IVF services. Major players in the IVF services market are Ambroise Par Group, amedes MVZ Köln GmbH, AMP Centre St Roch, AVA Clinic Scanfert, Bangkok IVF center, Betamedics, Bloom Fertility and Healthcare, Bourn Hall Fertility Centre, Biofertility Centre and Chelsea and Westminster Hospital (Assisted Conception Unit). Western Europe was the largest region in the IVF services market in 2022. North America was the second largest region in global IVF services market. The regions covered in the global IVF services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the IVF services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The IVF services market includes revenues earned by entities by providing services such as conventional insemination services, and intracytoplasmic sperm injection services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global IVF services market is segmented - 1) By Cycle Type: Fresh IVF Cycles(Non-donor), Thawed IVF Cycles(Non-donor), Donor Egg IVF Cycles 2) By Service Provider: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By End User: Fertility Clinics, Hospitals & Other Settings

Hormonal contraceptive refers to a method of birth control that stops pregnancy using hormones. There are numerous types. Some can be undone, while others are irreversible. Some varieties can also aid in the prevention of STDs. The main types of products in oral contraceptive pills are injectable birth control, emergency contraceptive pills, vaginal rings, and others. Any class of synthetic steroid hormones which inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior lobe of the pituitary gland in the female body is known as oral contraceptive pills or birth control pills. The different hormones include progestin-only, and combined hormones and are used by hospitals, homecare settings, gynecologycenters, clinics, and ambulatory surgical centers. It is distributed through various channels such as drug stores, gynecology or fertility clinics, e-commerce, and others. The hormonal contraceptives market research report is one of a series of new reports from The Business Research Company that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptive market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hormonal contraceptives market size will grow from $13.47 billion in 2022 to $13.78 billion in 2023 at a compound annual growth rate (CAGR) of 2.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hormonal contraceptives market size is expected to grow to $14.56 billion in 2027 at a CAGR of 1.4%. Increased awareness about the benefits and use of contraceptives is a major factor driving the hormonal contraceptives market. According to the World Health Organization (WHO), 16 million girls worldwide aged 15-19 give birth every year which accounts for approximately 11% of all births globally. To prevent these unplanned births global awareness programs such as It’s your life, it’s your future by the WHO and world contraception day was initiated. The London Summit on Family Planning urged governments, international agencies, and another private sectors to commit to improving access to voluntary family planning. This gave rise to the global partnership, Family Planning 2020 (FP2020). FP2020 has created momentum worldwide on issues such as access to contraceptives, more innovation, and greater accountability in family planning efforts. For example, India will have spent USD$3 billion by 2020 to spread awareness and improve family planning in the country. Moreover, in 2020, according to the United Nations Department of Economic and Social Affairs, about 1.1 billion women aged between 15 and 49 are considered to need family planning. The market for hormonal contraceptive drugs is restrained by the growing use of biologics in place of traditional chemical drugs. Biologics are medicines containing one or more substances derived from a biological source like micro-organisms, animal cells, or human cells. The ability to interact with specific targets puts these medicines above any other drugs, thus hampering the market of chemical-hormonal contraceptive drugs. Companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. The pill is already being sold as an over-the-counter product. Some of the top companies that produce and sell chewable low-dose oral contraceptives, for instance, are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. Manufacturers in the hormonal contraceptives market should abide by many strict regulations about labeling hormonal contraceptives, and are all supervised by regulatory authorities. For instance, the US FDA has drafted a new set of guidance and labeling recommendations in the hormonal contraceptives market. The main purpose of PLR is to enhance the safety and usage of the particular prescribed drug by providing healthcare providers with clear prescription information (PI). The FDA mandates all hormonal contraceptives to mention the effectiveness of the drug in preventing STDs and any other relevant information regarding the effectiveness of the drug. The FDA considers that communicating information regarding pregnancy rates to the users of these contraceptive drugs is essential for safety and effective usage. Major players in the hormonal contraceptives market are Bayer AG, Merck & Co. Inc., Pfizer, Allergan, Afaxys Inc., TevaPharma Industries Ltd., Agile Therapeutics, HLL Lifecare Limited, Lupin Pharmaceuticals Inc. and Piramal Healthcare Limited. North America was the largest region in the hormonal contraceptives market in 2022. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market during the forecast period. The regions covered in the global hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global hormonal contraceptives market is segmented - 1) By Product: Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Other Products 2) By End Users: Hospitals, Homecare Settings, Gynaecology Centers, Clinics, Ambulatory surgical centers 3) By Hormones: Progestin-Only, Combined Hormones 4) By Distribution Channel: Drug Stores, Gynaecology/ Fertility Clinics, E-Commerce, Other Distribution Channels

Lateral Flow Immunoassay (LFIA) based rapid test is a simple technology-based diagnostic device that is used to determine the presence of a target such as pathogens or biomarkers in samples collected from the human body. These samples may include urine, saliva, blood, sweat and other fluids. The main techniques in lateral flow immunoassay-based rapid testing are competitive assay, sandwich assay, and multiplex detection assay. The competitive assay is used to assess the existence of a target, such as pathogens or biomarkers, in the samples. The applications are infectious disease, pregnancy and fertility, toxicology, and others that are used in hospitals and clinics, diagnostic laboratory, home care, and others. The lateral flow immunoassay (LFIA) based rapid test market research report is one of a series of new reports from The Business Research Company that provides lateral flow immunoassay (LFIA) based rapid test market statistics, including lateral flow immunoassay (LFIA) based rapid test industry global market size, regional shares, competitors with a lateral flow immunoassay (LFIA) based rapid test market share, detailed lateral flow immunoassay (LFIA) based rapid test market segments, market trends and opportunities, and any further data you may need to thrive in the lateral flow immunoassay (LFIA) based rapid test industry. This lateral flow immunoassay (LFIA) based rapid test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global lateral flow immunoassay (LFIA) based rapid test market size is declined from $10.14 billion in 2022 to $9.19 billion in 2023 at a compound annual growth rate (CAGR) of -9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global lateral flow immunoassay (LFIA) based rapid test market size is expected to decline to $7.32 billion in 2027 at a CAGR of -5.5%. The demand for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market. Point-of-care (POCT) testing is essential for rapid on-site diagnosis and treatment. The most important features for current POCT diagnostic systems are a quick analysis time with a test-to-answer format. Lateral flow immunoassays (LFIA) are widely used as POCTs due to their speed and precision, simplicity, and low cost. For instance, the recent outbreak of coronavirus disease (COVID-19) has increased the significance of these devices to rapid screening and surveillance. Acro Biotech COVID-19 Rapid POC CE-IVD is a lateral flow immunoassay that quantifiably assesses the existence of patient-generated IgG and IgM antibodies to SARS-CoV-2, the causative agent of novel coronaviral disease COVID-19. These antibodies may be detected in whole blood, serum, or plasma samples in the test cassette. OZO has developed three different variations of its products using the Latex Enhanced Lateral Flow Immunoassays (LFIAs) method for testing COVID-19. Therefore, the need for point-of-care testing under home care settings is expected to drive the Lateral Flow Immunoassay (LFIA) Based Rapid Test market. Low sensitivity of Lateral Flow Immunoassay (LFIA) Based Rapid Test is expected to limit the market. The sensitivity of the test is mainly the ability of the test to correctly identify those with the disease, which is low for Lateral Flow Immunoassay (LFIA) Based Rapid Test compared to other methods that may, in some cases, require a re-test for confirmation. according to a study conducted by researchers, including those from the Harvard medical school in the USA and also the University of British Columbia, Canada. The medical databases and preprint servers were searched from January 1 to April 30, 2020, for studies measuring the sensitivity and specificity of the COVID-19 antibody test compared to the control test. It had been found that pooled sensitivities were consistently lower for the lateral flow immunoassay (LFIA) test compared to other test methods. The low level of sensitivity is anticipated to restrain the market growth for Lateral Flow Immunoassay (LFIA) based rapid test. Companies are collaborating to launch new products. In May 2020, Lateral Flow Diagnostic Company Mologic Ltd., which has teamed up with Biosure Ltd., the developer of the only CE-approved HIV home testing kit, to develop a COVID-19 antibody self-test. The companies combine Mologic's validated IgG lateral flow test strip with Biosure's test kit. In July 2020, MP Biomedicals Asia-Pacific Pte Ltd collaborated with a Singapore company A*STAR to create the ASSURE® SARS-CoV-2 IgG / IgM rapid antibody test kit to detect IgG and IgM antibodies in a person infected with SARS-CoV-2. The kit delivers precise results in very less time as less as 15 minutes and uses the lateral flow method. In April 2020, True Diagnostics, a leading US-based Point of Care (POC) company, partnered with Veravas and Infectolab Americas to create and distribute a fast, point-of-care immunoassay for SARS-CoV-2, the VeraTest SARS-CoV-2 IgA / IgG Fast Test will be developed to detect immunoglobulin A and immunoglobulin G antibodies to SARS-CoV-2 in the blood within 15 minutes. The test combines True Diagnostics, TrueDx lateral flow immunoassay technology with Veravas, VeraPrep clean, and VeraPrep capture technologies designed to remove cross-reaction antibodies and ensure the detection of only SARS-CoV-2-specific antibodies. Veravas is an emerging US-based diagnostic company. Infectolab Americas is a US-based laboratory specialized in lab testing for tick-borne disease. Major players in the lateral flow immunoassay (LFIA) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Danaher Corporation, Siemens AG, Becton, Dickinson and Company, bioMérieux, Bio-Rad Laboratories, Thermo Fisher Scientific, QIAGEN NV, and Hologic Inc. North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2022. Asia-Pacific was the second largest region in the global lateral flow immunoassay (LFIA) based rapid test market. The regions covered in the global lateral flow immunoassay (LFIA) based rapid test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the lateral flow immunoassay (LFIA) based rapid test market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. Lateral Flow Immunoassay (LFIA) based rapid test market consits of sales of conjugarte pads, nitrocellulose membrane and absorbent pad. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global lateral flow immunoassay (LFIA) based rapid test market is segmented - 1) By Technique: Competitive Assay, Sandwich Assay, Multiplex Detection Assay 2) By End User: Hospital & Clinic, Diagnostic Laboratory, Home Care, Other End Users 3) By Application: Infectious Disease, Pregnancy & Fertility, Toxicology, Other Applications